Tag: BIV201

January 16, 2018

BioVie Reviews Key Accomplishments from 2017 and Updates Phase 2a Clinical Trial

BioVie (OTCQB: BIVI), reviewed key milestones achieved over the past year and provided a general update on the progress of...
December 11, 2017

BioVie Obtains FDA Fast Track Designation for BIV201

BioVie announced the FDA granted the company a fast track designation for their orphan drug candidate BIV201.
September 28, 2017

BioVie Announces First Patient Dosed in Phase 2a Clinical Trial

BioVie reported the dosing for the first patient in its phase 2a clinical trial of BIV201 for the treatment of...
September 14, 2017

BioVie Enrolls First Patient in BIV201 Trial

BioVie confirmed enrollment of the first patient in the Company's mid-stage clinical trial of BIV201.
August 29, 2017

BioVie Reports Fiscal Year 2017 Financial Results

BioVie reported its financial report for the fiscal year 2017 and provided shareholders with a clinical development progress.
July 26, 2017

BioVie Files Patent Application in Japan

BioVie filed an application for patent coverage of their new drug candidate BIV201 in Japan.
May 24, 2017

BioVie Gets US Patent for New Drug

BioVie received clearance from the US Patent and Trademark Office regarding the company's new drug candidate treating patients with advanced...